Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
US Stock MarketDetailed Quotes
ANTX AN2 Therapeutics
- 1.280
- +0.060+4.92%
Trading Apr 30 12:58 ET
38.53MMarket Cap-0.74P/E (TTM)
1.280High1.230Low8.04KVolume1.220Open1.220Pre Close10.03KTurnover0.05%Turnover RatioLossP/E (Static)30.10MShares3.07052wk High0.47P/B22.62MFloat Cap0.87052wk Low--Dividend TTM17.67MShs Float23.580Historical High--Div YieldTTM4.10%Amplitude0.870Historical Low1.248Avg Price1Lot Size
About AN2 Therapeutics Company
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.
Company Profile
SymbolANTX
Company NameAN2 Therapeutics
Listing DateMar 25, 2022
Issue Price15.00
Founded2017
CEOMr. Eric Easom
MarketNASDAQ
Employees22
Fiscal Year Ends12-31
Address1800 El Camino Real,Suite D
CityMenlo Park
ProvinceCalifornia
CountryUnited States of America
Zip Code94027
Phone1-650-331-9090
Company Executives
- Name
- Position
- Salary
- Eric Easom
- Chairman of the Board, Chief Executive Officer and President
- 1.67M
- Lucy O. Day
- Chief Financial Officer and Principal Accounting Officer
- 812.70K
- Stephen David Prior
- Chief Strategy Officer
- --
- Joshua M. Eizen, J.D.
- Chief Legal Officer and Chief Operating Officer
- 1.06M
- Dr. Sanjay Chanda, PhD
- Chief Development Officer
- --
- Stephanie Wong
- Independent Director
- 158.51K
- Patricia Martin
- Independent Director
- 159.17K
- Margaret M. FitzPatrick, M.A.
- Lead Independent Director
- 159.08K
- Kabeer Aziz
- Independent Director
- 148.84K
- Joseph S. Zakrzewski
- Independent Director
- 169.93K
- Gilbert Lynn Marks, M.D.
- Independent Director
- 149.87K
- Dr. Rob Readnour, PhD
- Independent Director
- 150.15K
- Dr. Melvin K. Spigelman,M.D.
- Independent Director
- 147.01K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now